

**Supplementary Table 5.** Aggregated study-level data meta-analysis: Subgroup analysis for (A) Hepatocellular carcinoma, (B) cirrhosis, (C) mortality, and (D) HBsAg seroclerance in CHB patients with and without concomitant FLD

(A) Hepatocellular carcinoma

Studies		Events/patients	Incidence per 1,000 person-years	$I^2$	P-value
<b>Subgroup</b>					
<b>Diagnosis</b>					
<i>Imaging</i>					
Overall	2	285/7,480	2.2 (0.00–5.3)	98.2	
CHB-no FL	2	224/5,166	6.0 (2.3–9.8)	91.3	0.27
CHB-FL	2	61/2,314	9.4 (4.7–14.1)	88.7	
<i>Biopsy</i>					
Overall	5	108/2,493	6.5 (3.7–9.4)	83.6	
CHB-no FL	5	40/1,705	2.9 (1.3–4.5)	39.2	0.002
CHB-FL	5	68/788	12.6 (6.7–18.5)	63.5	
<i>Transient elastography</i>					
Overall	4	125/4,041	12.5 (2.1–22.9)	93.6	
CHB-no FL	4	81/2,133	13.6 (2.5–24.7)	89.5	0.6028
CHB-FL	4	44/1,908	9.6 (0.00–19.5)	87.1	
<b>Ethnicity</b>					
<i>Asian</i>					
Overall	9	497/12,796	8.7 (4.1–13.3)	89.3	
CHB-no FL	9	339/8,200	7.4 (2.8–12.0)	86.5	0.3703
CHB-FL	9	158/4,596	10.7 (5.1–16.2)	86.4	
<i>Non-Asian</i>					
Overall	2	21/1,218	3.1 (0.00–8.2)	92.6	
CHB-no FL	2	6/804	1.1 (0.00–2.8)	54	0.4222
CHB-FL	2	15/414	4.9 (0.00–14.1)	91.4	
<b>Population size</b>					
<i>&lt;500</i>					
Overall	4	80/1,214	11.4 (5.2–17.6)	75.5	
CHB-no FL	5	84/989	7.2 (0.3–14.2)	78.6	0.5799
CHB-FL	8	34/1,390	9.8 (4.1–15.4)	88.1	
<i>≥500</i>					
Overall	7	438/12,800	5.6 (1.0–10.1)	94.2	
CHB-no FL	6	307/8,015	5.5 (0.6–10.4)	94.8	0.5604
CHB-FL	3	93/3,620	9.0 (0.0–19.7)	90	
<b>Treatment</b>					
<i>Untreated</i>					
Overall	3	112/3,647	10.4 (0.5–20.4)	92	
CHB-no FL	3	65/1,927	9.6 (0.00–20.0)	91.1	0.8938
CHB-FL	3	47/1,720	10.6 (0.2–21.1)	90.8	
<i>Mixed treated &amp; untreated</i>					
Overall	7	381/10,033	4.7 (2.1–7.2)	92.6	

**Supplementary Table 5.** Continued

Studies		Events/patients	Incidence per 1,000 person-years	$I^2$	P-value
CHB-no FL	7	263/6,889	2.9 (1.4–4.4)	91.4	0.0861
CHB-FL	7	118/3,144	8.3 (2.3–14.3)	90.1	
<i>Treated</i>					
Overall	1	25/334	23.3 (14.1–32.4)	N/A	
CHB-no FL	1	17/188	28.1 (14.7–41.5)	N/A	0.2234
CHB-FL	1	8/146	17.0 (5.2–28.8)	N/A	

**Supplementary Table 5.** Continued  
(B) Cirrhosis

Studies		Events/Patients	Incidence rate per 1,000 person-years	$I^2$	P-value
Subgroup					
Diagnosis					
<i>Imaging</i>					
Overall	2	759/6,941	6.6 (0.0–13.8)	94.9	
CHB-no FL	2	561/4,728	6.0 (0.0–15.9)	98.3	0.5814
CHB-FL	2	198/2,206	8.3 (7.1–9.4)	0	
<i>Biopsy</i>					
Overall	2	40/267	13.1 (7.6–18.7)	39.6	
CHB-no FL	2	36/186	12.8 (8.6–17.0)	0	0.4082
CHB-FL	2	4/81	8.8 (0.4–17.2)	0	
Ethnicity					
<i>Asian</i>					
Overall	3	43/7,103	7.5 (2.4–12.6)	87.9	
CHB-no FL	3	565/4,813	6.8 (0.0–13.6)	96.6	0.6784
CHB-FL	3	202/2,283	8.3 (7.1–9.4)	0	
<i>Non-Asian</i>					
Overall	1	32/105	15.6 (10.2–21.0)		
CHB-no FL	1	32/101	13.7 (8.9–18.4)		0.3009
CHB-FL	1	0/4	5.4 (0.0–20.3)		
Population size					
<i>&lt;500</i>					
Overall	3	43/422	9.2 (1.5–16.8)	96.10	
CHB-no FL	3	36/269	7.6 (0.0–15.7)	91.6	0.9968
CHB-FL	3	7/146	7.6 (2.0–13.3)	0	
<i>&gt;500</i>					
Overall	1	756/6,786	10.1 (9.4–10.9)	N/A	
CHB-no FL	1	561/4,645	11.0 (10.1–11.9)	N/A	0.0002
CHB-FL	1	195/2,141	8.3 (7.1–9.5)	N/A	
Treatment					
<i>Untreated</i>					
Overall	2	35/253	9.0 (0.0–21.5)	93.8	
CHB-no FL	2	32/184	7.1 (0.0–19.6)	95.5	0.9261
CHB-FL	2	7/146	6.4 (0.0–13.2)	0	
<i>Mixed treated &amp; untreated</i>					
Overall	2	764/6,948	10.1 (9.4–10.9)	0	
CHB-no FL	2	565/4,730	11.0 (10.1–11.9)	0	0.0004
CHB-FL	2	199/2,218	8.3 (7.2–9.5)	0	
Treated (no study)					

**Supplementary Table 5.** Continued

(C) Mortality

Studies		Events/Patients	Incidence rate per 1,000 person-years	$I^2$	P-value
<b>Subgroup</b>					
<b>Diagnosis</b>					
<i>Imaging</i>					
Overall	1	430/6,786	5.1 (2.9–7.2)	N/A	
CHB-no FL	1	287/4,645	5.6 (5.0–6.3)	N/A	<0.01
CHB-FL	1	64/2,141	2.7 (2.1–3.4)	N/A	
<i>Biopsy</i>					
Overall	3	59/1,902	4.4 (1.4–7.4)	85.7	
CHB-no FL	3	29/1,291	2.9 (0.5–5.2)	45	0.24
CHB-FL	3	30/611	5.9 (1.4–10.3)	70.3	
<i>Transient elastography</i>					
Overall	1	20/578	8.7 (4.9–12.5)	N/A	
CHB-no FL	1	15/298	13.5 (6.6–20.3)	N/A	0.03
CHB-FL	1	5/280	4.8 (0.6–9.0)	N/A	
<b>Ethnicity</b>					
<i>Asian</i>					
Overall	4	410/8,742	4.8 (2.3–7.4)	92.6	
CHB-no FL	4	327/5,951	6.2 (2.0–10.4)	93.7	0.14
CHB-FL	4	83/2,791	3.0 (2.2–3.8)	0	
<i>Non-Asian</i>					
Overall	1	20/524	6.5 (3.7–9.4)	N/A	
CHB-no FL	1	4/283	2.4 (0.0–4.8)	N/A	<0.01
CHB-FL	1	16/241	11.4 (5.8–17.0)	N/A	
<b>Population size</b>					
<i>&lt;300</i>					
Overall	3	1,391	6.6 (4.9–8.4)	0	
CHB-no FL	3	26/685	7.1 (0.9–13.3)	81	0.63
CHB-FL	4	35/891	5.4 (2.4–8.4)	55.4	
<i>≥300</i>					
Overall	2	7,875	3.4 (0.7–6.0)	97	
CHB-no FL	2	305/5,549	3.8 (0.3–7.4)	97.5	0.55
CHB-FL	1	64/2,141	2.7 (2.1–3.4)	N/A	
<b>Treatment</b>					
<i>Untreated</i>					
Overall	1	20/524	6.5 (3.7–9.4)	N/A	
CHB-no FL	1	4/283	2.4 (0.0–4.8)	N/A	<0.01
CHB-FL	1	16/241	11.4 (5.8–17.0)	N/A	
<i>Mixed treated &amp; untreated</i>					
Overall	4	410/8,742	4.8 (2.3–7.4)	92.6	
CHB-no FL	4	327/5,951	6.2 (2.0–10.4)	93.7	0.15
CHB-FL	4	83/2,791	3.0 (2.2–3.8)	0	

*Treated (no study)*

**Supplementary Table 5.** Continued  
(D) HBsAg seroclearance

Studies		Events/Persons	Incidence rate per 1,000 person-years	$I^2$	P-value
<b>Subgroup</b>					
<i>Diagnosis</i>					
<i>Imaging</i>					
Overall	4	819/8,575	27.9 (0.0–63.2)	99.0	
CHB-no FL	4	455/5,587	26.5 (0.0–62.7)	96.2	0.87
CHB-FL	4	364/2,736	30.6 (0.3–60.9)	96.1	
<i>Biopsy</i>					
Overall	1	5/89	61.3 (7.6–115.0)	N/A	
CHB-no FL	1	3/58	56.4 (0.0–120.3)	N/A	0.81
CHB-FL	1	2/31	70.4 (0.0–167.9)	N/A	
<i>Transient elastography</i>					
Overall	2	96/1,050	28.5 (16.7–40.3)	73.6	
CHB-no FL	2	52/553	24.9 (0.0–53.1)	93.2	0.77
CHB-FL	2	44/497	29.3 (20.7–38.0)	0	
<b>Population size</b>					
<i>&lt;300</i>					
Overall	4	169/978	42.0 (6.2–77.9)	96	
CHB-no FL	4	78/541	36.7 (0.0–76.8)	93.5	0.78
CHB-FL	4	91/437	44.1 (10.3–77.9)	89.3	
<i>&gt;300</i>					
Overall	3	751/8,736	17.9 (2.0–33.8)	98	
CHB-no FL	3	432/5,657	19.1 (0.0–38.3)	97.1	0.98
CHB-FL	3	319/2,827	19.4 (7.2–31.5)	96.2	
<b>Treatment</b>					
<i>Untreated</i>					
Overall	2	164/875	58.6 (9.7–107.5)	96.2	
CHB-no FL	2	98/483	61.5 (16.0–107.0)	91.8	0.82
CHB-FL	2	66/392	53.6 (0.7–106.5)	93.1	
<i>Mixed treated &amp; untreated</i>					
Overall	3	699/8,346	13.4 (4.9–21.8)	96.9	
CHB-no FL	3	390/5,416	9.9 (4.2–15.7)	94.4	0.18
CHB-FL	3	309/2,678	20.3 (6.4–34.1)	96	
<i>Treated</i>					
Overall	1	5/89	61.3 (7.6–115.0)	N/A	
CHB-no FL	1	3/58	56.4 (0.0–120.3)	N/A	0.81
CHB-FL	1	2/31	70.4 (0.0–167.9)	N/A	

CHB, chronic hepatitis B; FL, fatty liver; FLD, fatty liver disease; N/A, not available.